Phase I Study of Intramuscular (IM) Injections of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia. PLX-PAD Are Mesenchymal-Like Stromal Cells Derived From a Full Term Placenta.

Trial Profile

Phase I Study of Intramuscular (IM) Injections of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia. PLX-PAD Are Mesenchymal-Like Stromal Cells Derived From a Full Term Placenta.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 May 2015

At a glance

  • Drugs PLX PAD (Primary)
  • Indications Peripheral arterial disorders
  • Focus Adverse reactions
  • Sponsors Pluristem Therapeutics
  • Most Recent Events

    • 18 May 2015 According to a Pluristem Therapeutics media release, the PLX cell program in critical limb ischemia has been selected for the European Medicines Agency's Adaptive Pathways pilot project.
    • 27 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top